Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00087854 · ClinicalTrials.gov registry record · Phase 1
Study of Individualized Amonafide to Treat Prostate Cancer
A Phase 1 study of Prostate Cancer, sponsored by Xanthus Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 8
- Study locations
NCT00087854: Completed Phase 1 study of Prostate Cancer, sponsored by Xanthus Pharmaceuticals.
NCT00087854 is a Phase 1 study of Prostate Cancer that has completed, run by Xanthus Pharmaceuticals. The registered enrollment target is 40 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (93% lower). The trial reports 8 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00087854, a Phase 1 study of Prostate Cancer, has completed, sponsored by Xanthus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to assess the safety and efficacy of Amonafide in men with androgen-independent prostate cancer, assigned to individualized doses of Amonafide based on acetylator phenotype information (doses adjusted on individual metabolism).
Conditions Studied
Interventions
- DRUG Amonafide L-malate (drug)
Study Locations (8)
California
- USC Norris Comprehensive Cancer Center - Los Angeles
Maryland
- Cancer Center at John Hopkins - Baltimore
Missouri
- Barnard Cancer Center - St Louis
New Jersey
- Cancer Institute of New Jersey - New Brunswick
New York
- Herbert Irving Cancer Center - New York
Ohio
- The Cleveland Clinic - Cleveland
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Washington
- Seattle Cancer Care Alliance - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2004-03 |
| Est. Completion | 2005-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00087854
The ClinicalTrials.gov registry entry for NCT00087854 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Xanthus Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Amonafide L-malate (drug) is the first listed.
NCT00087854 reports 8 study locations spanning 8 distinct geographic areas - top geographies include California, Maryland, Missouri.
Frequently Asked Questions
What is clinical trial NCT00087854 about?
NCT00087854 is a clinical study titled "Study of Individualized Amonafide to Treat Prostate Cancer". The purpose of this study is to assess the safety and efficacy of Amonafide in men with androgen-independent prostate cancer, assigned to individualized doses of Amonafide based on acetylator phenotype information (doses adjusted on individual metabolism).
What is the current status of trial NCT00087854?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2004-03. Estimated completion is 2005-12.
What conditions does trial NCT00087854 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00087854?
The interventions under investigation include: Amonafide L-malate (drug) (DRUG).
Who is sponsoring clinical trial NCT00087854?
This trial is sponsored by Xanthus Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00087854 being conducted?
This trial has 8 study locations across California, Maryland, Missouri, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.